Abstract:Chronic organ injury leads to fibrosis and eventually organ failure. Fibrosis is characterized by excessive synthesis, remodeling, and contraction of extracellular matrix produced by myofibroblasts. Myofibroblasts are the key cells in the pathophysiology of fibrotic disorders and their differentiation can be triggered by multiple stimuli. To develop anti-fibrotic therapies, it is of paramount importance to understand the molecular basis of the signaling pathways contributing to the activation and maintenance of myofibroblasts. Several signal transduction pathways, such as transforming growth factor (TGF)-β, Wingless/Int (WNT), and more recently yes-associated protein 1 (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling, have been linked to the pathophysiology of fibrosis. Activation of the TGF-β1-induced SMAD complex results in the upregulation of genes important for myofibroblast function. Similarly, WNT-stabilized β-catenin translocates to the nucleus and initiates transcription of its target genes. YAP and TAZ are two transcriptional co-activators from the Hippo signaling pathway that also rely on nuclear translocation for their functioning. These three signal transduction pathways have little molecular similarity but do share one principle: the cytosolic/nuclear regulation of its transcriptional activators. Past research on these pathways often focused on the isolated cascades without taking other signaling pathways into account. Recent developments show that parts of these pathways converge into an intricate network that governs the activation and maintenance of the myofibroblast phenotype. In this review, we discuss the current understanding on the signal integration between the TGF-β, WNT, and YAP/TAZ pathways in the development of organ fibrosis. Taking a network-wide view on signal transduction will provide a better understanding on the complex and versatile processes that underlie the pathophysiology of fibrotic disorders.

Transforming growth factor- signaling: From tissue fibrosis to therapeutic opportunities

Transforming growth factor-β signaling: From tissue fibrosis to therapeutic opportunities

Transforming Growth Factor-Β1 Induced Epithelial-Mesenchymal Transition in Hepatic Fibrosis.

Targeting TGF-β signal transduction for fibrosis and cancer therapy

New Insights into TGF-β/Smad Signaling in Tissue Fibrosis.

Targeting Fibrosis: Mechanisms and Clinical Trials

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Transforming Growth Factor- Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

Targeting fibrosis, mechanisms and cilinical trials

MicroRNAs in Transforming Growth Factor-Beta Signaling Pathway Associated With Fibrosis Involving Different Systems of the Human Body

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts

Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis

Deciphering the cellular mechanisms underlying fibrosis-associated diseases and therapeutic avenues

Transforming Growth Factor-β Pathway and Molecular Treatment of Liver Fibrosis

Wnt/beta-catenin signaling: a promising new target for fibrosis diseases.

TGF-β As A Master Regulator of Aging-Associated Tissue Fibrosis

Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge

TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases

Therapeutic Targets for the Treatment of Cardiac Fibrosis and Cancer: Focusing on TGF-β Signaling